On March 27, closed Medfield its new issue. The issue was subscribed by 552 new shareholders, which together provides the Company more than 6.9 million SEK. The issue is followed by a listing on AktieTorget, with the first trading day May 2

The issue is a success for the Company. During the road show I have met many enthusiastic people who understand the benefits of the products we develop. Considerable interest has been from health professionals and patient groups. Many of these have also subscribed for shares, notes a satisfied Patrik Dahlqvist, CEO of Medfield Diagnostics. Although the issue was not completely overbooked, we will have space to perform the development work that we describe in the memorandum. Next for Medfieldis to complete the clinical testing of Strokefinder R10 that is on going at Sahlgrenska University Hospital. In addition, further sales of Strokefinder R10 this year.

See also press release.